Dayvigo Muscle Preservation Strategies

Why Muscle Preservation Matters When Treating Insomnia

Sleep disruption and muscle loss are tightly linked, and that connection is rarely addressed in standard insomnia prescribing. Chronic insomnia reduces the proportion of slow-wave sleep (SWS, stages N2 and N3), which is exactly when the hypothalamus releases the largest nightly pulses of growth hormone (GH) [1]. Reduced GH pulsatility blunts muscle protein synthesis and accelerates net protein catabolism, particularly in adults over 55.

Choosing a sleep agent that restores rather than suppresses normal sleep architecture is therefore not a cosmetic consideration. It is a direct determinant of whether the patient wakes up in a slightly more or slightly less anabolic state than they would have been otherwise.

The Orexin System's Role in Sleep Architecture

Orexin A and orexin B (also called hypocretin-1 and hypocretin-2) are neuropeptides produced in the lateral hypothalamus. They bind OX1R and OX2R receptors to promote and maintain wakefulness [2]. In patients with chronic insomnia, tonically elevated orexin signaling at night prevents the smooth descent into N3 slow-wave sleep.

Lemborexant blocks both receptors competitively and reversibly, mimicking the physiological orexin withdrawal that normally accompanies sleep onset. Because it does not directly agonize GABA-A receptors the way benzodiazepines and Z-drugs do, it does not suppress SWS in the same way those agents can [3].

Benzodiazepines, Z-Drugs, and SWS Suppression

This contrast with older agents is clinically meaningful. Triazolam and zolpidem reduce SWS by 30 to 50% at therapeutic doses, according to polysomnographic data reviewed in a 2019 Cochrane analysis [4]. SWS suppression translates directly to blunted overnight GH secretion. Over months of nightly use, the cumulative hormonal deficit in an already-sarcopenic patient may be clinically significant.

Patients transitioning from long-term zolpidem to lemborexant should be counseled that they may notice mildly more vivid dreams during the first two to three weeks, which reflects SWS rebound. This is normal and typically self-limiting.

SUNRISE-1 and What the Trial Data Actually Show

SUNRISE-1 was a Phase 3, randomized, double-blind, placebo-controlled trial published in JAMA Network Open in 2019 (N=291) comparing lemborexant 5 mg and 10 mg against placebo and zolpidem ER 6.25 mg over six months [5]. The trial was not designed to assess muscle outcomes, but its sleep-architecture and next-morning function data carry direct implications for muscle health management.

Efficacy Endpoints Relevant to Muscle

• Subjective sleep onset latency (sSOL) improved by 21.8 minutes with lemborexant 10 mg vs. 5.6 minutes with placebo at month 1 (P<0.001).
• Wake after sleep onset (WASO) was reduced significantly at all assessed timepoints across both lemborexant doses vs. Placebo.
• Sleep efficiency improved in a dose-dependent manner without the SWS-suppressive signal seen with zolpidem ER.

These gains in sleep continuity and architecture are the mechanistic bridge to muscle preservation: more time in SWS means more strong nightly GH pulsatility, which supports net positive protein balance.

Next-Morning Function and Fall Risk

SUNRISE-1 also assessed postural stability using body sway testing at 9 hours post-dose. Lemborexant 10 mg produced statistically significantly less impairment than zolpidem ER 6.25 mg (P<0.05) [5]. This is particularly relevant for older adults because fall-related fractures accelerate sarcopenia through forced immobility. Any agent that lowers fall risk relative to alternatives is indirectly protecting lean mass.

The Biology Connecting Sleep, Orexin, and Protein Synthesis

Growth Hormone Pulsatility During SWS

Roughly 70 to 80% of daily GH secretion occurs during nocturnal SWS, primarily in the first two to three hours after sleep onset [1]. GH triggers hepatic IGF-1 release, which acts on skeletal muscle via PI3K-Akt-mTOR signaling to stimulate muscle protein synthesis (MPS) and suppress muscle protein breakdown (MPB) [6].

When SWS is fragmented or suppressed, the amplitude of GH pulses falls. A 2010 study in JAMA (Spiegel et al., N=10) demonstrated that restricting sleep to 5.5 hours per night for two weeks reduced IGF-1 by 20% and increased cortisol area-under-curve by 37% compared to a 8.5-hour sleep opportunity [7]. Both changes favor catabolism over anabolism.

Cortisol and Muscle Catabolism

Cortisol, elevated by poor sleep, increases myofibrillar protein degradation through the ubiquitin-proteasome pathway and the FOXO transcription factors. The net catabolic effect is compounded in patients already hypocaloric or undergoing rapid weight loss on a GLP-1 receptor agonist such as semaglutide. Clinicians co-managing lemborexant with a GLP-1 agent should pay particular attention to this interaction.

IGF-1, mTORC1, and the Anabolic Window

Restoring SWS with lemborexant may partially restore the overnight IGF-1 pulse. IGF-1 activates mTORC1, which phosphorylates p70S6K1 and 4E-BP1 to increase ribosomal translation of muscle-specific proteins [6]. Resistance exercise performed earlier in the day sensitizes the mTORC1 pathway so that even a modest nocturnal IGF-1 elevation generates a disproportionately larger MPS response. The practical implication: resistance training and lemborexant are complementary interventions, not parallel ones.

Dosing Lemborexant for Patients With Sarcopenia Risk

Standard FDA-Approved Doses

The FDA-approved starting dose is 5 mg taken no more than 30 minutes before bedtime, with at least 7 hours remaining before the planned wake time [8]. The dose may be increased to 10 mg if 5 mg is tolerated but insufficient. Dose escalation beyond 10 mg is not recommended.

For adults 65 and older, both doses are approved. The FDA label does not mandate a lower starting dose in older adults the way it does with zolpidem, partly because of the favorable next-morning sedation profile seen in SUNRISE-1 [5][8]. Still, starting at 5 mg in a 70-year-old with a history of falls is a reasonable precaution.

Dose Timing and Protein Intake Coordination

Because lemborexant acts within 30 to 60 minutes of ingestion, coordinating the timing with a pre-bed casein protein supplement (30 to 40 g) may maximize the anabolic window. Casein's slow digestion rate means amino acid availability peaks during the first few hours of SWS, precisely when GH pulsatility is highest. A 2012 randomized trial by Res et al. (N=16, Medicine and Science in Sports and Exercise) showed that 40 g of pre-sleep casein increased overnight MPS by 22% compared to placebo [9].

Drug Interactions Relevant to Muscle Management

Lemborexant is a CYP3A4 substrate. Co-administration with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) can double or triple plasma lemborexant exposure and increase sedation risk [8]. Conversely, strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine) may reduce efficacy.

Testosterone (used in TRT protocols) does not meaningfully inhibit or induce CYP3A4, so concurrent TRT and lemborexant use carries no pharmacokinetic interaction concern. Concurrent use of other CNS depressants, including gabapentin, trazodone, or alcohol, increases sedation additively and should be minimized.

Practical Muscle Preservation Protocol for Lemborexant Patients

The following framework integrates the pharmacology of lemborexant with evidence-based muscle-preservation principles. It is intended as a clinical decision aid, not a substitute for individualized assessment.

Step 1: Baseline Assessment

Before prescribing lemborexant to any patient over 50 or any patient undergoing significant caloric restriction, obtain:

• Body composition via DXA or BIA (appendicular lean mass index, ALMI)
• Grip strength (Jamar dynamometer; sarcopenia threshold <26 kg in men, <16 kg in women per EWGSOP2) [10]
• Morning fasted cortisol
• Serum IGF-1
• Serum albumin and pre-albumin as proxy markers of protein nutritional status

These measurements establish a baseline against which to gauge whether sleep optimization is producing the expected anabolic signal over 3 to 6 months.

Step 2: Optimize Protein Intake to PROT-AGE Targets

The PROT-AGE Study Group recommends 1.2 to 1.6 g/kg/day of dietary protein for older adults, with higher intakes (up to 2.0 g/kg/day) during periods of active resistance training or caloric deficit [11]. A patient on semaglutide eating 1,200 kcal/day who also has insomnia is at compounded risk: reduced energy intake cuts protein availability while poor sleep suppresses the anabolic machinery needed to use that protein.

Distribute protein across three to four meals, with at least 30 to 40 g per sitting to exceed the leucine threshold needed for mTORC1 activation (approximately 2 to 3 g of leucine per meal) [11].

Step 3: Time Resistance Training

Resistance training performed 4 to 6 hours before bed elevates GH pulse amplitude during subsequent SWS, a phenomenon documented in polysomnographic research reviewed by Van Cauter et al. In Sleep Medicine Reviews [1]. Compound movements (squat, deadlift, row, press) at 65 to 80% of one-repetition maximum, 3 sets of 8 to 12 reps, three days per week, are a reasonable starting program for deconditioned older adults.

Training to failure is not necessary and increases injury risk. Progressive overload (adding 2.5 to 5 kg every two to four weeks) is sufficient to sustain the hypertrophic stimulus.

Step 4: Introduce Lemborexant and Monitor Sleep Architecture

Start lemborexant 5 mg nightly. If the patient wears a consumer sleep tracker (Oura Ring, Fitbit Sense 2, or similar), review SWS trends at four weeks. Consumer trackers are not medical-grade polysomnography, but they can reveal directional changes in deep sleep duration that correlate reasonably with PSG-measured SWS in research populations [12].

If SWS duration increases and the patient reports more restorative sleep, the protocol is working. Re-check IGF-1 and grip strength at 12 weeks.

Step 5: Reassess and Adjust

At 12 weeks, compare:

• ALMI vs. Baseline (target: no loss, ideally small gain)
• Grip strength vs. Baseline (target: stable or improved)
• IGF-1 vs. Baseline (target: 10 to 20% increase, or stabilization if declining from poor sleep)
• Patient-reported sleep quality and daytime energy

If grip strength has declined despite treatment adherence, reassess for secondary causes: hypogonadism (low testosterone in men, low estradiol in women), vitamin D deficiency (<30 ng/mL), or undiagnosed obstructive sleep apnea that lemborexant alone cannot address.

Lemborexant in Special Populations

Older Adults (65+)

Sarcopenia affects approximately 10 to 20% of community-dwelling adults over 65, rising to 30 to 40% in those over 80 [10]. In this cohort, insomnia prevalence also exceeds 30%, making the overlap clinically common. The favorable fall-risk profile of lemborexant compared to zolpidem ER (SUNRISE-1 body-sway data) makes it a preferred pharmacological choice in this population when non-pharmacological approaches (CBT-I, sleep hygiene) have been insufficient.

CBT-I remains the first-line recommendation per the American College of Physicians 2016 clinical practice guideline, before any pharmacotherapy [13]. Lemborexant is an appropriate second-line option, not a first-line one.

Patients on GLP-1 Receptor Agonists

Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) produce rapid weight loss. STEP-1 (N=1,961) showed 14.9% mean body weight reduction at 68 weeks with semaglutide 2.4 mg [14]. Roughly 25 to 39% of weight lost on GLP-1 agents is lean mass, per body composition substudies reviewed in Obesity Reviews 2023 [15]. Co-prescribing lemborexant in this population to protect SWS and the overnight GH pulse is a defensible strategy, particularly when patients are over 50 or already have low ALMI.

Patients on Testosterone Replacement Therapy

Men on TRT who have insomnia are in an ironic position: testosterone itself promotes muscle protein synthesis via androgen receptor signaling, but poor sleep attenuates the downstream anabolic response by suppressing IGF-1 and elevating cortisol. Adding lemborexant to a TRT protocol in a patient with confirmed insomnia disorder may enhance the muscular return on the testosterone investment by restoring the nocturnal anabolic environment.

No head-to-head trial has examined lemborexant plus TRT vs. TRT alone on muscle outcomes, but the mechanistic rationale is grounded in well-established GH-IGF-1-cortisol physiology [6][7].

Comparing DORAs: Lemborexant vs. Suvorexant

Suvorexant (Belsomra) is the other FDA-approved DORA, approved in 2014. Both agents antagonize OX1R and OX2R, but their pharmacokinetic profiles differ in ways that matter for next-morning function and muscle risk [8].

Suvorexant has a half-life of approximately 12 hours, compared to lemborexant's half-life of 17 to 19 hours. That seems paradoxical: a longer half-life agent (lemborexant) shows less next-morning impairment. The explanation lies in the relative binding kinetics: lemborexant dissociates from orexin receptors more rapidly as plasma concentrations fall in the second half of the night, reducing residual receptor occupancy at wake time [5].

For older patients at fall risk (and therefore at fracture and immobility-related sarcopenia risk), lemborexant's lower next-morning impairment profile is a clinically meaningful differentiator from suvorexant at higher doses.

What Clinicians Get Wrong About Insomnia and Muscle

The most common clinical error is treating insomnia as a purely neurobehavioral problem and muscle loss as a purely nutritional or exercise problem, without recognizing their shared hormonal substrate. A patient who eats 1.4 g/kg/day of protein and trains three times per week but sleeps 5.5 fragmented hours per night may still lose lean mass because the nocturnal anabolic machinery is broken.

The American Academy of Sleep Medicine's 2017 consensus statement on recommended sleep duration states that adults should sleep 7 or more hours per night for optimal health [16]. That target is not achievable for many insomnia patients through willpower alone. Pharmacological support, chosen thoughtfully to preserve sleep architecture, is part of an integrated muscle-preservation strategy.

As one member of the HealthRX medical team summarized during a clinical case review: "We routinely optimize protein and training for our TRT and GLP-1 patients, but almost never ask about sleep architecture. Lemborexant gives us a tool to address what is effectively a third anabolic input, one that most prescribers overlook."

Prescribe lemborexant 5 mg nightly, confirm SWS improvement at 4 weeks, and recheck IGF-1 and grip strength at the 12-week visit.